This company listing is no longer active
Medlab Clinical Crecimiento futuro
Future controles de criterios 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Medlab Clinical.
Información clave
-44.7%
Tasa de crecimiento de los beneficios
-44.7%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs | 16.1% |
Tasa de crecimiento de los ingresos | 41.7% |
Rentabilidad financiera futura | n/a |
Cobertura de analistas | Low |
Última actualización | 04 May 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now
Oct 06Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?
Oct 05What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay
Feb 21Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years
Dec 30Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future
Nov 22Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
6/30/2024 | 4 | -22 | N/A | N/A | 1 |
6/30/2023 | 7 | -14 | N/A | N/A | 1 |
6/30/2022 | 2 | -8 | -9 | -9 | N/A |
3/31/2022 | 1 | -9 | -10 | -10 | N/A |
12/31/2021 | 4 | -12 | -11 | -11 | N/A |
9/30/2021 | 4 | -12 | -11 | -11 | N/A |
6/30/2021 | 1 | -10 | -10 | -10 | N/A |
3/31/2021 | 1 | -10 | -9 | -9 | N/A |
12/31/2020 | 1 | -11 | -8 | -8 | N/A |
9/30/2020 | 2 | -12 | -10 | -9 | N/A |
6/30/2020 | 3 | -13 | -11 | -10 | N/A |
3/31/2020 | 4 | -12 | -11 | -11 | N/A |
12/31/2019 | 4 | -12 | -12 | -12 | N/A |
9/30/2019 | 5 | -10 | -11 | -11 | N/A |
6/30/2019 | 5 | -8 | -11 | -10 | N/A |
3/31/2019 | 5 | -7 | -9 | -9 | N/A |
12/31/2018 | 5 | -6 | -7 | -7 | N/A |
9/30/2018 | 4 | -5 | -6 | -6 | N/A |
6/30/2018 | 4 | -5 | -5 | -5 | N/A |
3/31/2018 | 4 | -4 | -5 | -5 | N/A |
12/31/2017 | 5 | -4 | -5 | -5 | N/A |
9/30/2017 | 5 | -4 | -4 | -4 | N/A |
6/30/2017 | 4 | -4 | -4 | -4 | N/A |
3/31/2017 | 4 | -4 | -4 | -4 | N/A |
12/31/2016 | 4 | -4 | -4 | -4 | N/A |
9/30/2016 | 3 | -4 | -4 | -4 | N/A |
6/30/2016 | 3 | -3 | -4 | -4 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: MDC is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: MDC is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: MDC is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: MDC's revenue (41.7% per year) is forecast to grow faster than the Australian market (4.8% per year).
Ingresos de alto crecimiento: MDC's revenue (41.7% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if MDC's Return on Equity is forecast to be high in 3 years time